On this page

What the dated primary record establishes

GSK’s February 2022 filed announcement described Gilead paying ViiV Healthcare US$1.25 billion upfront and a 3% royalty on specified U.S. sales. It described distribution by ViiV’s ordinary shareholdings after Shionogi contingent consideration and applicable tax. GSK’s stated ordinary shareholding was 78.3%.

The 2022 financial note later reports that ViiV received the upfront payment on 15 February 2022. A received upfront payment does not establish future royalties or GSK’s final net cash. The worldwide patent-licence description and the U.S. royalty base are separate scopes.

Sources: GSK, filed with the U.S. SEC: Complete filed announcement; Financial Considerations and shareholder/CCL notes, plus cautionary statement GSK, SEC-filed financial note 7: Note 7 footnote 2, actual 15 February 2022 receipt and defined US royalty scope/period

Test the decision in your own operation

For your licensing or jointly owned U.S. business, draw the money route through the legal entities. The customer’s payment, the recipient’s earnings and the parent’s distribution are three different records. Use this original ELN bridge with the actual agreements.

Record to establishEvidence to bringOwner decision
Paying customer and baseNamed payer, covered products, geography, rate and periodWhich transaction actually earns the fee?
Receiving entityContractual recipient, bank receipt and its own obligationsWhat belongs to that company before owners receive anything?
Prior deductionsSupported contingent payments, taxes and other applicable adjustmentsWhich amounts come before the shareholder allocation?
Owner distributionActual economic rights, approvals, currency and payment dateWhat can this parent receive, and when?

Resolve the next commitment

Fictional example: assume a jointly owned recipient has US$100,000 available before an agreed US$20,000 prior deduction, with the remaining US$80,000 distributable 60/40. The 60% owner’s amount is US$48,000. Applying 60% to the original US$100,000 would overstate that amount by US$12,000. These invented terms are not ViiV’s calculation or tax treatment.

Use Relationship factsheet to record the payer, recipient, shareholders and payment responsibilities. Keep the detailed distribution calculation and dated cash schedule with the actual agreements. A headline royalty rate cannot replace that entity-by-entity work.

Scope

  • The historical announcement and financial note do not disclose the entire settlement, current royalty receipts, net parent distributions or another company’s tax treatment.
  • The fictional allocation assumes the deduction precedes distribution; actual preference rights, liabilities and distribution restrictions can change the result.

Next step

A recipient-to-parent cash bridge identifying equity rights, deductions, distribution approval and currencies without assuming gross royalty equals owner cash. Identify the entity receiving the fee, prior obligations and the actual rights governing each owner’s payment.

Terms used here
Royalty base
The sales or other defined measure to which an agreed royalty rate applies; it is not automatically every product or worldwide sale.
Contingent consideration
An additional payment obligation whose amount depends on specified future events or performance; its contract and accounting treatment need separate reading.
Sources & review notes

Access dates show when a source was retrieved. Review dates show when its meaning was checked. Editing this guide does not recheck the law.

GSK’s filed ViiV–Gilead settlement announcement

GSK, filed with the U.S. SEC

Passage, dates and research notes

company-regulatory-filing · Complete filed announcement; Financial Considerations and shareholder/CCL notes, plus cautionary statement

Accessed: 2026-11-16T20:15:20.581972+00:00 · Meaning reviewed: 2026-11-16T20:17:44.802833+00:00 · Next review target: 2026-12-16

The announcement describes expected payments and the recipient’s shareholder arrangements. Ordinary share percentages are not assumed to equal every earnings right or gross cash distribution.

GSK 2022 financial note on ViiV settlement receipt

GSK, SEC-filed financial note 7

Passage, dates and research notes

company-regulatory-filing · Note 7 footnote 2, actual 15 February 2022 receipt and defined US royalty scope/period

Accessed: 2026-11-16T20:15:20.887253+00:00 · Meaning reviewed: 2026-11-16T20:17:44.802833+00:00 · Next review target: 2026-12-16

The note reports the upfront payment actually received, separately from future royalty terms and unrelated operating items. The SEC filing date was checked against the retained official index.

Your learning

Bookmark this guide or mark it as read.

Learning library
Progress privacy

Saving is off by default. Without it, progress lasts only on this page. If you turn it on, this browser profile stores public content IDs and the progress you record. Anyone sharing the profile could see them. No plan inputs or contact details are included. Reset or export in learning settings.

This is a reading aid, not evidence of disclosure delivery, expertise or legal approval.